Lead Product(s): BIO201
Therapeutic Area: Ophthalmology Product Name: Macuneos
Highest Development Status: Preclinical Product Type: Small molecule
Deal Size: $1.1 million Upfront Cash: Undisclosed
Deal Type: Funding April 29, 2021
Macuneos (BIO201) is an orally administered small molecule in development for the treatment of diseases of the retina, or retinopathies. Biophytis has completed preclinical cellular and animal studies of Macuneos (BIO201) for the treatment of retinopathies.
Lead Product(s): IC 800
Therapeutic Area: Ophthalmology Product Name: IC 800
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: IACTA PHARMACEUTICALS
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 07, 2021
Under the terms of these agreements, Pharmaleads and Pharmaleads Greater China have granted IACTA an exclusive, worldwide, royalty-bearing license to lead the clinical and commercial development of IC800 (acute) and IC805 and other DENKI drugs from Pharmaleads’ portfolio.